secwatch.observer — SEC 8-K summary
======================================

Issuer:     Summit Therapeutics Inc. (SMMT)
CIK:        0001599298
Form:       8-K
Filed at:   2024-05-24T23:59:59+00:00
Accession:  0001599298-24-000092
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Summit partner Akeso wins China NMPA approval for ivonescimab in EGFR-mutated NSCLC
--------------------------------------------------------------------------------

- NMPA approved ivonescimab + chemo for EGFR-mutated advanced non-squamous NSCLC after TKI failure.
- First regulatory approval for ivonescimab globally; based on HARMONi-A Phase III trial.
- Median PFS by IRRC: 7.06 mo (ivonescimab) vs 4.80 mo (chemo alone); HR 0.46 (95% CI 0.34-0.62).
- Grade ≥3 TEAEs: 61.5% in ivonescimab arm vs 49.1% in chemo arm; mostly chemo-related.
- Approval does not affect Summit's US/global development plan; HARMONi and HARMONi-3 trials continue.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1599298/000159929824000092/0001599298-24-000092-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1599298/000159929824000092/smmt-20240524.htm
  HTML page:      https://secwatch.observer/filing/0001599298-24-000092

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer